Advertisement
Skip to Content

Immutep Ltd PRRUF Stock Quote

| Rating as of

PINX: PRRUF

Last close prices updated as of Feb 01, 2023, 2:32 PM EST | USD
  • Last Close 0.1954
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Value
  • Day Range 0.20  –  0.20
  • Year Range 0.16  –  0.30
  • Market Cap 171.7741 Mil
  • Volume / Avg 4,400.0 /  5,202.4
  • Price / Sales 981.09
  • Price / Book 2.59
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis PRRUF

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics PRRUF

Company Profile PRRUF

Business Description

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its lead product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives most of the revenue from the sale of the products.

Contact
264 George Street, Level 33, Australia Square
Sydney, NSW, 2000, AUS
Industry Biotechnology
Employees 35

FAQs for Immutep Ltd Stock

No. PRRUF does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

PRRUF’s market cap is 171.77 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

PRRUF’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

PRRUF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare PRRUF’s historical performance against its industry peers and the overall market.